Johnson & Johnson said it will file for FDA approval for Abiomed's Impella ECP heart pump following positive clinical trial results. J&J acquired Abiomed in late 2022 for $16.6 billion. · MedTech Dive ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
DANVERS, Mass. – October 28, 2024 – Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ...
Results were presented at Transcatheter Cardiovascular Therapeutics, or TCT, 2024 conference from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial ...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results